DK1677787T3 - Kombinationer af kaliumkanalåbnere og natriumkanalinhibitorer eller aktive stoffer, der påvirker natriumkanaler, til behandling af smertefulde tilstande - Google Patents

Kombinationer af kaliumkanalåbnere og natriumkanalinhibitorer eller aktive stoffer, der påvirker natriumkanaler, til behandling af smertefulde tilstande

Info

Publication number
DK1677787T3
DK1677787T3 DK04790551.8T DK04790551T DK1677787T3 DK 1677787 T3 DK1677787 T3 DK 1677787T3 DK 04790551 T DK04790551 T DK 04790551T DK 1677787 T3 DK1677787 T3 DK 1677787T3
Authority
DK
Denmark
Prior art keywords
sodium
combinations
active substances
affect
painful conditions
Prior art date
Application number
DK04790551.8T
Other languages
English (en)
Inventor
Robert Hermann
Mathias Locher
Istvan Szelenyi
Kay Brune
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Application granted granted Critical
Publication of DK1677787T3 publication Critical patent/DK1677787T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04790551.8T 2003-10-23 2004-10-18 Kombinationer af kaliumkanalåbnere og natriumkanalinhibitorer eller aktive stoffer, der påvirker natriumkanaler, til behandling af smertefulde tilstande DK1677787T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10349729 2003-10-23
DE10359335A DE10359335A1 (de) 2003-10-23 2003-12-16 Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
PCT/EP2004/011718 WO2005039576A1 (de) 2003-10-23 2004-10-18 Kombinationen aus kaliumkanalöffnern und natriumkanalinhibitoren oder natriumkanal beeinflussenden wirkstoffen zur behandlung von schmerzzuständen

Publications (1)

Publication Number Publication Date
DK1677787T3 true DK1677787T3 (da) 2013-03-18

Family

ID=34524051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04790551.8T DK1677787T3 (da) 2003-10-23 2004-10-18 Kombinationer af kaliumkanalåbnere og natriumkanalinhibitorer eller aktive stoffer, der påvirker natriumkanaler, til behandling af smertefulde tilstande

Country Status (18)

Country Link
EP (1) EP1677787B1 (da)
JP (1) JP4855941B2 (da)
CN (1) CN1871000B (da)
AU (1) AU2004283472B2 (da)
CA (1) CA2542434C (da)
CY (1) CY1113789T1 (da)
DE (1) DE10359335A1 (da)
DK (1) DK1677787T3 (da)
ES (1) ES2401146T3 (da)
HK (1) HK1096308A1 (da)
HR (1) HRP20130176T1 (da)
NO (1) NO335896B1 (da)
NZ (1) NZ546522A (da)
PL (1) PL1677787T3 (da)
PT (1) PT1677787E (da)
RU (1) RU2355395C2 (da)
SI (1) SI1677787T1 (da)
WO (1) WO2005039576A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
AT500999A1 (de) * 2004-11-11 2006-05-15 Sanochemia Pharmazeutika Ag Tolperison enthaltendes veterinärmedizinisches präparat zur oralen verabreichung bei der behandlung von säugetieren, wie hunden mit degenerativen, spinalen symptomen
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CN101563085A (zh) 2006-08-23 2009-10-21 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CA2670966A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CN104784409A (zh) * 2015-03-30 2015-07-22 曹仁俊 一种治疗截瘫神经痛的中药组合物
TW202128162A (zh) 2019-11-08 2021-08-01 加拿大商再諾製藥公司 憂鬱症之治療方法
PE20231815A1 (es) 2021-02-09 2023-11-16 Xenon Pharmaceuticals Inc Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2000143510A (ja) * 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CA2370030C (en) * 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
NO20062336L (no) 2006-07-11
RU2006117525A (ru) 2007-12-10
CN1871000B (zh) 2010-06-09
NZ546522A (en) 2009-09-25
PT1677787E (pt) 2013-03-07
JP2007509100A (ja) 2007-04-12
EP1677787A1 (de) 2006-07-12
CN1871000A (zh) 2006-11-29
AU2004283472B2 (en) 2010-02-11
EP1677787B1 (de) 2012-12-12
JP4855941B2 (ja) 2012-01-18
CA2542434C (en) 2013-06-25
AU2004283472A1 (en) 2005-05-06
CY1113789T1 (el) 2016-07-27
HK1096308A1 (en) 2007-06-01
DE10359335A1 (de) 2005-05-25
ES2401146T3 (es) 2013-04-17
HRP20130176T1 (hr) 2013-03-31
WO2005039576A1 (de) 2005-05-06
RU2355395C2 (ru) 2009-05-20
PL1677787T3 (pl) 2013-05-31
CA2542434A1 (en) 2005-05-06
NO335896B1 (no) 2015-03-16
SI1677787T1 (sl) 2013-04-30

Similar Documents

Publication Publication Date Title
DK1677787T3 (da) Kombinationer af kaliumkanalåbnere og natriumkanalinhibitorer eller aktive stoffer, der påvirker natriumkanaler, til behandling af smertefulde tilstande
NL300960I2 (nl) Combinatie van daunorubicine en cytarabine
FI20041499A0 (fi) Viestitntäverkkojen yli lähetettävien viestien prosessointi
PH12012501544A1 (en) Inhibitors of poly (adp-ribose) polymerase
IL175074A0 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatement, modification and management of pain
MXPA05013822A (es) Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
UA103492C2 (ru) Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
DK1494692T3 (da) Topiske, farmaceutiske sammensætninger, der omfatter proanthocyanidiner, glycyrrhetinsyre og telmestein til behandlingen af dermatitis
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
DK1827441T3 (da) Kombinationer til behandling af sygdomme, som involverer celleproliferation
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
DK1761266T3 (da) Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
MX2009007053A (es) Inhibidores de poli (adp-ribosa) polimerasa.
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
ATE510822T1 (de) Kaliumkanalinhibitoren
CL2011000147A1 (es) Compuestos derivados de carbamato de alquiltiazol, inhibidores de la enzima faah; composicion farmaceutica que los comprende; procedimiento de preparacion de estos; y sus usos en el tratamiento de dolores agudos o cronicos, vertigo, vomitos, nauseas, epilepsias, entre otras.
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
ATE471147T1 (de) Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
WO2006075012A3 (en) Pyrrolodihydroisoquinolines as antiproliferative agents
IS7960A (is) Samsetningar og aðferðir til þess að meðhöndla krabbamein með því að nota IGSF9 og LIV-1
FI20055081A (fi) Viestintäjärjestelmä sekä henkilökohtainen viestintävälipalvelin
WO2007130353A3 (en) Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress
DK1783105T3 (da) Mørtelsammensætning, fremgangsmåde til fremstilling og anvendelse deraf